South Korean medical device manufacturer Wontech closed 5.35% higher following its strategic partnership announcement with Chinese medical aesthetic group Yestar. According to the company’s disclosure on September 11, 2026, shares finished the trading day at 5,120 KRW, up from the previous session, as investors responded to plans for expanded local network utilization, product supply, and clinical collaboration in China.
## Partnership Scope and Clinical Training
The agreement bridges Wontech and Yestar, a major player operating across 21 Chinese cities through 33 medical institutions. According to the September 11 report, the collaboration centers on launching clinical education programs for flagship aesthetic devices, specifically the Lavieen and Picocare laser systems. Yestar’s extensive footprint across major metropolitan health and beauty facilities provides a direct distribution and training pipeline. Medical staff at these 33 locations will receive specialized instruction on device operation, integrating Wontech’s technology into routine clinical practice for local patients seeking advanced dermatological treatments.
## Market Reaction and Financial Context
The stock movement reflects investor confidence in cross-border medical device expansion.
Related reading